30 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 30 of 30 clinical reviews.
A clinical guide to Aetna (CVS Health) coverage for Vyleesi (bremelanotide), including prior authorization criteria, step therapy requirements, formulary tier, appeal strategies, and manufacturer savings options.
A clinical and insurance guide to Anthem (Elevance Health) coverage of Vyleesi (bremelanotide) for HSDD, including prior authorization criteria, step therapy requirements, appeal strategies, and cost alternatives.
Find out whether Humana covers Vyleesi (bremelanotide) for HSDD, what prior-authorization criteria apply, how formulary tiers work, and exactly how to appeal a denial in 2024.
Kaiser Permanente coverage details for Vyleesi (bremelanotide), including formulary status, prior authorization requirements, step therapy, appeal options, and cost-saving alternatives for HSDD treatment.
Evidence-based protocols for switching between Vyleesi (bremelanotide) and flibanserin (Addyi), off-label testosterone, or other HSDD treatments, including washout timing, efficacy expectations, and safety considerations.
Evidence-based dosing guide for Vyleesi (bremelanotide) in adult women ages 30-49 with HSDD. Covers the FDA-approved 1.75 mg subcutaneous dose, injection timing, frequency limits, and clinical trial data from RECONNECT.
A clinician-grade review of every known and theoretical drug-drug interaction with bremelanotide (Vyleesi), including oral bioavailability effects, cardiovascular overlaps, and melanocortin pathway crosstalk.
Evidence-based guide to bremelanotide (Vyleesi) dosing adjustments for patients with hepatic impairment, including pharmacokinetic data, FDA labeling, and clinical recommendations.
Evidence-based guide to bremelanotide (Vyleesi) use in adults 65 and older, covering dose adjustments, safety considerations, renal decline, and clinical monitoring for geriatric patients with HSDD.
Evidence-based monitoring guide for bremelanotide (Vyleesi) in premenopausal women aged 30 to 49 with HSDD. Covers blood pressure checks, nausea management, injection-site reactions, melanocyte screening, and follow-up timelines.
Clinical guidance on bremelanotide (Vyleesi) overdose management, symptoms of accidental excess dosing, expected adverse effects, and when to seek emergency care.
A clinical review of bremelanotide (Vyleesi) real-world evidence from registries, post-market surveillance, and observational studies for HSDD in premenopausal women.
Current regulatory status of bremelanotide (Vyleesi) across the United States, European Union, Canada, and United Kingdom, including approval history, mechanism of action, and clinical evidence from the RECONNECT trials.
A guide to bremelanotide (Vyleesi) safety in women ages 18 to 29, covering nausea rates, blood pressure effects, contraceptive interactions, fertility considerations, and dosing from the RECONNECT trials.
A guide to bremelanotide (Vyleesi) safety in premenopausal women aged 30 to 49, covering adverse-event rates from the RECONNECT trials, blood-pressure warnings, nausea management, and long-term use considerations.
A guide to bremelanotide (Vyleesi) safety for adults aged 50 to 64, covering cardiovascular risk, nausea, blood pressure changes, polypharmacy, and perimenopause considerations.
A deep dive into bremelanotide (Vyleesi) cardiovascular effects, blood pressure changes, long-term safety data from RECONNECT, and clinical guidance for patients with cardiac risk factors.
An evidence-based comparison of compounded bremelanotide and FDA-approved Vyleesi for HSDD, covering pharmacology, safety, efficacy data from RECONNECT, dosing, and how to choose between options.
Vyleesi runs $850 to $950 per carton (about $215-$240 per dose), versus $800-$1,000 for brand Addyi or $30-$80 for generic flibanserin.
The complete history of bremelanotide (Vyleesi), from its origins as a melanocortin analog to FDA approval for hypoactive sexual desire disorder in premenopausal women.
A physician-level explanation of how bremelanotide (Vyleesi) activates melanocortin-4 receptors in the CNS to restore sexual desire in premenopausal women with HSDD.
Evidence-based guidance on Vyleesi (bremelanotide) missed-dose scenarios, including timing windows, dose adjustments, and when to contact your prescriber. prepared by the HealthRX.com Editorial Team.
When do Vyleesi patents expire? A clinical breakdown of bremelanotide patent coverage, Hatch-Waxman exclusivity, and the realistic timeline for a generic or biosimilar alternative.
A source-checked review of Vyleesi pharmacokinetics, including current FDA values for bioavailability, Tmax, Cmax, volume of distribution, metabolism, half-life, excretion, organ impairment, and oral-drug interactions.
A clinician-level guide to the bremelanotide (Vyleesi) pre-surgery hold window, covering FDA labeling, cardiovascular pharmacology, anesthesia interactions, and practical perioperative management protocols.
A guide to bremelanotide (Vyleesi) safety during pregnancy and breastfeeding, covering mechanism of action, FDA labeling, reproductive toxicology data, and practical clinical guidance.
A deep dive into bremelanotide (Vyleesi) and renal function: pharmacokinetics, clinical trial safety data, FDA labeling guidance, and practical prescribing advice for patients with kidney concerns.
A clinician-level review of bremelanotide (Vyleesi) safety signals, FDA actions, post-marketing data, and the melanocortin mechanism behind HSDD treatment in premenopausal women.
Everything clinicians and patients need to know about bremelanotide (Vyleesi) storage temperatures, shelf life, auto-injector stability, and what to do if a dose is compromised.
Complete clinical guide to bremelanotide (Vyleesi) dosing for young adults aged 18 to 29, including injection technique, timing, side-effect management, and RECONNECT trial data.